Based on the information available, there is no specific guidance from the manufacturer or regulatory agencies regarding the waiting period between receiving the COVID-19 vaccine and starting Cosentyx (secukinumab) treatment. The Centers for Disease Control and Prevention (CDC) generally recommends that patients consult with their healthcare providers for personalized advice on timing vaccinations and starting new treatments [1].

Cosentyx is a prescription medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [2]. The COVID-19 vaccine is essential for protecting against the SARS-CoV-2 virus, and it is recommended for individuals to stay up-to-date with their vaccinations [3].

When considering the timing of starting Cosentyx after receiving the COVID-19 vaccine, it is crucial to weigh the potential risks and benefits. Factors such as the patient's overall health, immune status, and the urgency of starting the new treatment should be taken into account [1].

In summary, there is no universally applicable waiting period between receiving the COVID-19 vaccine and starting Cosentyx. Patients should consult their healthcare providers for personalized advice on the matter [1][2][3].

Sources:
[1] Centers for Disease Control and Prevention. (2022). Timing of Vaccination After Receiving Other Vaccines. <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/timing.html>
[2] Cosentyx (secukinumab) [prescribing information]. (2021). Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[3] Centers for Disease Control and Prevention. (2022). COVID-19 Vaccines. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html>